SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Shutterstock
After a Standout IPO and Series of Pivots, Rubius Closes its Doors
Rubius Therapeutics’ board of directors has approved a plan to liquidate and dissolve the company, the Massachusetts-based biotech announced in an SEC form 8-K filed Monday.
February 22, 2023
 · 
2 min read
 · 
Tristan Manalac
Drug Development
PTC Previews Key Spring Readouts in Full-Year 2022 Report
PTC Therapeutics reported Q4 and full-year 2022 results Tuesday ahead of a pivotal 2023 featuring three late-stage readouts in registration-directed trials.
February 22, 2023
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Actinium’s Targeted Radiotherapy for AML Called “Practice-Changing”
Actinium Pharmaceuticals’ Iomab-B met the primary endpoint in the Phase III SIERRA trial, demonstrating durable Complete Remission at six months.
February 21, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy Tomohiro Ohsumi/Getty Images
Drug Development
Takeda’s Vedolizumab Clears Phase III in aGvHD
Takeda’s vedolizumab met its primary endpoint in the Phase III GRAPHITE study, significantly improving event-free survival in patients with acute graft-versus-host disease.
February 20, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eric Dube, Travere CEO/Company Courtesy
FDA
Travere Scores Accelerated Approval for First Non-Immunosuppressive IgAN Therapeutic
The FDA granted accelerated approval Friday to Travere Therapeutics’ sparsentan, now to be marketed as Filspari, to reduce the burden of proteinuria in adults with primary IgA nephropathy.
February 20, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy of JHVEPhoto/Getty Images
Drug Development
Pfizer/Valneva Trial at Risk After Possible GCP Violations
Pfizer and Valneva are dropping approximately half of enrolled participants in the Phase III VALOR study for their Lyme disease vaccine candidate, VLA15.
February 17, 2023
 · 
2 min read
 · 
Tristan Manalac
Shutterstock
Drug Development
Newron’s Schizophrenia Candidate Gets Better Over Time
One-year data from a Phase II study of Newron’s schizophrenia candidate evenamide showed sustained efficacy and continued improvements in symptoms of psychosis and disease severity.
February 17, 2023
 · 
3 min read
 · 
Tristan Manalac
David R. Epstein, CEO of Seagen, Courtesy Bloomber
Drug Development
Seagen Mum on Merck Buyout Rumors as it Bats for Blockbuster with Adcetris
Seagen did not address rumors of a buyout from Merck during its fourth-quarter and full-year financial report. Instead, it focused on upcoming label expansions and its promising pipeline.
February 16, 2023
 · 
2 min read
 · 
Tristan Manalac
Business
Grifols Slashes 2,000 U.S. Jobs in Efficiency Bid
Spanish drugmaker Grifols announced a comprehensive plan Wednesday to improve its efficiency and cost-effectiveness – a move that will reportedly cost some 2,000 U.S. jobs.
February 16, 2023
 · 
2 min read
 · 
Tristan Manalac
John Tlumacki/The Boston Globe via Getty Images
Business
Biogen Expects Modest Leqembi Revenue as Aduhelm Takes Another Hit
Biogen’s 2022 fourth-quarter and full-year report comes the day after an additional warning on the company’s first Alzheimer’s drug came to light.
February 15, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy josefkubes/Getty Images_John Reed_courtes
Business
John Reed Jumps Ship at Sanofi to Helm J&J’s R&D
Fresh off of his Sanofi exit, John Reed is joining Johnson & Johnson, where he will serve as executive vice president, pharmaceuticals, R&D.
February 14, 2023
 · 
2 min read
 · 
Tristan Manalac
Chesnot/Getty Images
Business
Sanofi R&D Head Steps Down Ahead of Busy 2023 Schedule
Sanofi’s global head of R&D, John Reed, is leaving his position to pursue another opportunity outside the company, the French multinational announced Monday.
February 13, 2023
 · 
2 min read
 · 
Tristan Manalac
Aristea Team/Courtesy Photo
Drug Development
AstraZeneca Spin-off Aristea Folds After Safety Issues End Lead Program
Due to safety concerns, Aristea Therapeutics announced Friday that it was discontinuing the development of its Phase II lead program. As a result, the San Diego-based biotech is also dissolving its business.
February 13, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Financing concept/Getty Images
IPO Doors Creak Open as Mineralys Seeks $192M
Mineralys Therapeutics hopes to raise $192 million in its initial public offering - one week after Structure Therapeutics announced its own IPO.
February 10, 2023
 · 
2 min read
 · 
Tristan Manalac
Policy
Phathom Faces Another Delay with H. pylori, Esophagitis Drugs
The FDA issued complete response letters to Phathom Pharmaceuticals, flagging the presence of N-nitroso-vonoprazan (NVP) impurities in its Helicobacter pylori drug products.
February 10, 2023
 · 
2 min read
 · 
Tristan Manalac
Load More